Systematic reevaluation of gene polymorphism and osteosarcoma occurrence and prognosis#br#
GUO Jinrong1 MEI Qijie1 YUAN Changshen1 XU Wenfei2 YAO Hongyi3
1.Department of Orthopaedic Joint Diseases and Trauma, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530023, China;
2.Graduate School, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530023, China;
3.Department of Rehabilitation Medicine, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Hubei Province, Wuhan 430077, China
Abstract：Objective To reevaluate the published systematic evaluation of gene polymorphism and osteosarcoma occurrence and prognosis. Methods PubMed, Embase, Web of Science, Cochrane Library, CBM, CNKI, VIP, and Wanfang Data were searched to screen the systematic evaluation of gene polymorphism and the occurrence and prognosis of osteosarcoma. The search period was from the establishment of inception to April 2020. After independent literature screening, data extraction, and quality evaluation, AMSTAR2 scale was used to evaluate the quality of the methodology included in the study. Results In the end, 23 articles were included in the systematic evaluation, and AMSTAR2 scale results showed that three articles were of medium quality, 11 articles were of low quality, and nine articles were of extremely low quality. Conclusion The overall quality of evidence included in the study is low, the current research results show that gene polymorphism is closely related to the occurrence and prognosis of osteosarcoma, which provides new methods and ideas for the treatment of osteosarcoma patients. Due to the impact of the quality of the included research, more high-quality research is needed for further verification.
[1] Harrison DJ，Geller DS，Gill JD，et al. Current and future therapeutic approaches for osteosarcoma [J]. Expert Rev Anticancer Ther，2018，18（1）：39-50.
[2] Heymann D. Metastatic osteosarcoma challenged by regorafenib [J]. Lancet Oncol，2019，20（1）：12-14.
[3] Lettieri CK，Appel N，Labban N，et al. Progress and opportunities for immune therapeutics in osteosarcoma [J]. Immunotherapy，2016，8（10）：1233-1244.
[4] Xu Q，Zhang Z，Sun W，et al. Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population [J]. Mammalian genome，2017，28（5/6）：227-233.
[5] Cui Y，Zhu JJ，Ma CB，et al. Genetic polymorphisms in MMP 2，3 and 9 genes and the susceptibility of osteosarcoma in a Chinese Han population [J]. Biomarkers，2016，21（2）：160-163.
[6] Zhang N，Jiang Z，Ren W，et al. Association of polymorphisms in WWOX gene with risk and outcome of osteo-sarcoma in a sample of the young Chinese population [J]. Onco Targets Ther，2016，9：807-813.
[7] Qu WR，Wu J，Li R. Contribution of the GSTP1 gene polymorphism to the development of osteosarcoma in a Chinese population [J]. Genet Mol Res，2016，15（3）：1-6.
[8] 张方圆，沈傲梅，曾宪涛，等.系统评价方法学质量评价工具AMSTAR 2解读[J].中国循证心血管医学杂志，2018， 10（1）：14-18.
[9] 李夏西，肖颖.谷胱甘肽S-转移酶M1、T1基因多态性与骨肉瘤易感性的Meta分析[J].山东医药，2013，53（36）：11-13.
[10] Moghimi M，Sobhan MR，Jarahzadeh MH，et al. Association of GSTM1，GSTT1，GSTM3，and GSTP1 Genes Polymorphisms with Susceptibility to Osteosarcoma：a Case- Control Study and Meta-Analysis [J]. Asian Pac J Cancer Prev，2019，20（3）：675-682.
[11] Pu F，Chen F，Chen S，et al. Association between GSTP1 polymorphisms and prognosis of osteosarcoma in patients treated with chemotherapy：a meta-analysis[J]. Onco Targets Ther，2015，8：1835-1842.
[12] Han J，Deng W，Wang L，et al. Null genotypes of glutathione S-transferase μ1 and glutathione S-transferase θ1 are associated with osteosarcoma risk：A meta-analysis [J]. Oncol Lett，2015，9（4）：1912-1916.
[13] Lan J，Yang Q，Zhou M，et al. A meta-analysis of association between glutathione S-transferase gene polymorphism and osteosarcoma chemosensitivity in Chinese population [J]. J Cancer Res Ther，2016，12（Supplement）：64-67.
[14] 全忠，王帅，刘毅.谷胱甘肽S转移酶基因多态性与中国人群骨肉瘤化疗敏感性的meta分析[J].海南医学，2015，26（21）：3229-3233.
[15] Mehdinejad M，Sobhan MR，Mazaheri M，et al. Genetic Association between ERCC2，NBN，RAD51 Genern Variants and Osteosarcoma Risk：a Systematic Review andrnMeta-Analysis [J]. Asian Pac J Cancer Prev，2017，18（5）：1315-1321.
[16] Zhang H，Ge J，Hong H，et al. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population：a meta-analysis [J]. World J Surg Oncol，2017，15（1）：75.
[17] Sobhan MR，Forat Yazdi M，Mazaheri M，et al. Association between the DNA Repair Gene XRCC3 rs861539 Polymorphism and Risk of Osteosarcoma：a Systematic Review and Meta-Analysis [J]. Asian Pac J Cancer Prev，2017，18（2）：549-555.
[18] Li C，Yu X，Guo D，et al. Association between common polymorphisms in ERCC gene and prognosis of osteo-sarcoma in patients treated with chemotherapy：a meta-analysis [J]. Onco Targets Ther，2018，11：3495-3504.
[19] Wang Y，Wang G，Dong Z. Association of X-ray cross-complementing group 3 Thr241Met gene polymorphism with osteosarcoma risk and its development and prognosis [J]. J Cancer Res Ther，2018，14（Supplement）：S1178-S1182.
[20] Chen XJ，Tong ZC，Kang X，et al. ERCC polymorphisms and risk of osteosarcoma：a meta-analysis [J]. Eur Rev Med Pharmacol Sci，2018，22（20）：6658-6666.
[21] Zhang C，Hou WH，Ding XX，et al. Association of Cytotoxic T-lymphocyte Antigen-4 Polymorphisms with Malignant Bone Tumor Risk：A Meta-analysis [J]. Asian Pac J Cancer Prev，2016，17（8）：3785-3791.
[22] Yu F，Miao J. Significant association between cytotoxic T lymphocyte antigen 4 +49G＞A polymorphism and risk of malignant bone tumors [J]. Tumour Biol，2013，34（6）：3371-3375.
[23] Bilbao-Aldaiturriaga N，Patino-Garcia A，Martin-Guerrero I，et al. Cytotoxic T lymphocyte-associated antigen 4 rs231775 polymorphism and osteosarcoma [J]. Neoplasma，2017，64（2）：299-304.
[24] Chen Z，Guo J，Zhang K，et al. TP53 Mutations and Survival in Osteosarcoma Patients：A Meta-Analysis of Published Data [J]. Dis Markers，2016，2016：4639575.
[25] Huang X，Wu F，Zhang Z，et al. Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors：a meta-analysis [J]. Biosci Rep，2019，39（3）：BSR20181832.
[26] Zhao J，Chen ZQ，Li GW，et al. The associations of vascular endothelial growth factor gene polymorphisms with susceptibility to osteosarcoma：evidence from a meta-analysis [J]. Eur J Cancer Care（Engl），2017，26（5）：12513.
[27] Tang J，Shen L，Song S，et al. Polymorphisms in the MDM2 gene and risk of malignant bone tumors：a meta-analysis [J]. Tumour Biol，2014，35（1）：779-784.
[28] Wang Z，He ML，Zhao JM，et al. Meta-analysis of associations of the ezrin gene with human osteosarcoma response to chemotherapy and prognosis [J]. Asian Pac J Cancer Prev，2013，14（5）：2753-2758.
[29] Jiang L，Tao C，He A. Prognostic significance of p53 expression in malignant bone tumors：a meta-analysis [J]. Tumour Biol，2013，34（2）：1037-1043.
[30] Chang Z，Song R，Xu S，et al. CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population [J]. Tumour Biol，2014，35（7）：6809-6814.
[31] Jiang Y，Wang X，Cheng Y，et al. Associations between inflammatory gene polymorphisms（TNF- 308G A，TNF- 238G A，TNF-252A G，TGF-1 29T C，IL-6 174G C and IL-10 1082A G）and susceptibility to osteosarcoma：a meta-analysis and literature review [J]. Oncotarget，2017， 8（57）：97571-97583.
[32] 魏强，吴建臣.循证医学的最好证据——系统评价[J].中华泌尿外科杂志，2003，24（11）：69-70.
[33] 杨克虎，刘雅莉，袁金秋，等.发展和完善中的系统评价再评价[J].中国循证儿科杂志，2011，6（1）：54-57.
京公网安备 11010502046598号